Systematic analysis of funding awarded for viral hepatitis-related research to institutions in the United Kingdom, 1997-2010

Journal of Viral Hepatitis

Volumn 22, Issue 3, 2015, Pages 230-237

  Head, M G ^a   Fitchett, J R ^b   Cooke, G S ^c   Foster, G R ^d   Atun, R ^e  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

funding; hepatitis A; hepatitis B; hepatitis C; research

Indexed keywords

HEPATITIS C VACCINE;

ARTICLE; CLINICAL RESEARCH; DELTA AGENT HEPATITIS; FUNDING; HEPATITIS A; HEPATITIS B; HEPATITIS C; HEPATITIS E; HEPATITIS G; HUMAN; INVESTMENT; PATHOGENESIS; POLICY; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; RESEARCH PRIORITY; RESOURCE ALLOCATION; SYSTEM ANALYSIS; SYSTEMATIC REVIEW; UNITED KINGDOM; VACCINATION; VIRUS HEPATITIS; AWARDS AND PRIZES; ECONOMICS; FINANCIAL MANAGEMENT; GREAT BRITAIN; HEPATITIS; HISTORY; ORGANIZATION; ORGANIZATION AND MANAGEMENT; RESEARCH;

ACADEMIES AND INSTITUTES; AWARDS AND PRIZES; CAPITAL FINANCING; GREAT BRITAIN; HEPATITIS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; RESEARCH;

EID: 84923070765     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12300     Document Type: Article

References (13)

1. Jacobsen KH, Wiersma ST,. Hepatitis A virus seroprevalence by age and world region, 1990 and 2005. Vaccine 2010; 28 (41): 6653-6657.
2. Ly KN, Xing J, Klevens RM, et al,. Causes of death and characteristics of decedents with viral hepatitis, United States, 2010. Clin Infect Dis 2014; 58 (1): 40-49.
3. Van de Laar MJW, Lopalco PL,. World Hepatitis Day: a timely reminder of the challenges ahead. Euro Surveill 2008; 13 (21): pii: 18883.
4. Lavanchy D,. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11 (2): 97-107.
5. Rein DB, Stevens GA, Theaker J, et al,. The global burden of hepatitis E virus genotypes 1 and 2 in 2005. Hepatology 2012; 55 (4): 988-997.
6. European Centre for Disease Prevention and Control. Hepatitis B and C in the EU Neighbourhood: Prevalence, Burden of Disease and Screening Policies. Stockholm: European Centre for Disease Prevention and Control, 2010.
7. Balogun MA, Vyse AJ, Hesketh LM, et al,. Estimating hepatitis C infection acquired in England, 1986-2000. Epidemiol Infect 2009; 137 (9): 1249-1254.
8. Head MG, Fitchett JR, Cooke MK, et al,. UK investments in global infectious disease research 1997-2010: a case study. Lancet Infect Dis 2013; 13 (1): 55-64.
9. ResIn-Research Investments in Global Health. Available at: http://www.researchinvestments.org (accessed 4 July 2014).
10. World Health Organisation. The Global Burden of Disease: 2004 update. Geneva, Switzerland: World Health Organization, 2008.
11. Head MG, Fitchett JR, Cooke MK, et al,. Investments in respiratory infectious disease research 1997-2010: a systematic analysis of UK funding. BMJ Open 2014; 4 (3): e004600.
12. Cooke GS, Lemoine M, Thursz M, et al,. Viral hepatitis and the Global Burden of Disease: a need to regroup. J Viral Hepat 2013; 20 (9): 600-601.
13. Røttingen J-A, Regmi S, Eide M, et al,. Mapping of available health research and development data: what's there, what's missing, and what role is there for a global observatory? Lancet 2013; 382 (9900): 1286-307.